Conduit Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Conduit Pharmaceuticals has been growing earnings at an average annual rate of 61.4%, while the Life Sciences industry saw earnings growing at 16.5% annually.
Key information
61.4%
Earnings growth rate
71.4%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Conduit Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -2 | 6 | 0 |
| 31 Dec 23 | 0 | -1 | 5 | 0 |
| 30 Sep 23 | 0 | -5 | 6 | 0 |
| 30 Jun 23 | 0 | -8 | 6 | 0 |
| 31 Mar 23 | 0 | -6 | 4 | 0 |
| 31 Dec 22 | 0 | -5 | 3 | 0 |
| 30 Sep 22 | 0 | -2 | 2 | 0 |
Quality Earnings: ZK7 is currently unprofitable.
Growing Profit Margin: ZK7 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ZK7's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ZK7's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZK7 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-13%).
Return on Equity
High ROE: ZK7's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.